We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Alnylam Announces Closing of Previously Announced Strategic Alliance with Roche

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Alnylam Announces Closing of Previously Announced Strategic Alliance with Roche"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Alnylam Pharmaceuticals, Inc. has announced that completion of the closing for its previously announced alliance with Roche.

On July 9, 2007, Alnylam and Roche announced the signing of this alliance in which Roche has obtained a non-exclusive license to Alnylam's technology platform for developing RNAi therapeutics.

Roche is required to make aggregate payments to Alnylam of approximately $331.0 million, including an upfront cash payment within ten business days of the closing in connection with the license.

The Roche Venture Fund purchased 1.975 million shares of Alnylam common stock for an aggregate purchase price of approximately $42.5 million. Roche also completed the acquisition of Alnylam's European research site located in Kulmbach, Germany (Bavaria).